FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1999361421> ?p ?o ?g. }

• W1999361421 endingPage "351" @default.
• W1999361421 startingPage "345" @default.
• W1999361421 abstract "WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Atrial fibrillation (AF) is the most common rhythm disturbance in medical practice. • AF can be managed with the prevention of thromboembolism and either a rate control or rhythm control strategy; however, as both treatment strategies have important limitations, a preventative strategy could be a more attractive option. • Angiotensin‐converting enzyme inhibitors (ACE‐Is) and angiotensin‐II receptor blockers (ARBs) may play a role in preventing AF recurrence. WHAT THIS STUDY ADDS • The aim of the present review was to analyse evidence supporting the usefulness of renin–angiotensin system (RAS) inhibition in patients with AF and to focus on which specific subset of patients it most favours. • Although many studies and meta‐analysis have supported the advantage of RAS block in preventing AF recurrence, it is not possible to recommend the use of ACE‐Is and ARBs in routine clinical practice specifically to prevent AF. • As these drugs are safe and manageable, they should be considered the drugs of choice in patients with AF and coexisting clinical conditions such as hypertension, coronary disease, heart failure and diabetes mellitus. Atrial fibrillation (AF) is the most common rhythm disturbance in medical practice and represents a very expensive health problem. AF can be managed with the prevention of thromboembolism and either a rate control or rhythm control strategy. As both strategies have important limitations, probably a preventative strategy in patients at risk of developing arrhythmia can be a more attractive option. The renin–angiotensin system (RAS) seems to be involved in the genesis of arrhythmia by the following two mechanisms: the induction of atrial fibrosis and structural remodelling by mitogen‐activated protein kinase (MAPK) expression and reduction of collagenase activity; the induction of electrical remodelling by shortening of the atrial effective refractory period (AERP) and of the action potential duration. For these reasons it has been hypothesized that angiotensin‐converting enzyme inhibitors (ACE‐Is) and angiotensin‐II receptor blockers (ARBs) may play a role in preventing AF recurrence. The aim of the present review was to analyse evidence supporting the usefulness of RAS inhibition in patients with AF in order to focus on which specific subset of patients it would most favour. After reviewing the literature, we conclude that, although many studies and meta‐analyses have supported the advantage of RAS block in preventing AF recurrence, it is premature to recommend the use of ACE‐Is and ARBs specifically for the prevention of AF. However we believe that as these drugs are safe and manageable, they should be considered the drugs of choice in patients with AF and coexisting clinical conditions such as hypertension, coronary disease, heart failure and diabetes mellitus." @default.
• W1999361421 created "2016-06-24" @default.
• W1999361421 creator A5014426314 @default.
• W1999361421 creator A5017301961 @default.
• W1999361421 creator A5019974993 @default.
• W1999361421 creator A5034033183 @default.
• W1999361421 creator A5052505304 @default.
• W1999361421 date "2008-08-11" @default.
• W1999361421 modified "2023-10-17" @default.
• W1999361421 title "The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS" @default.
• W1999361421 cites W1543909448 @default.
• W1999361421 cites W164006490 @default.
• W1999361421 cites W1946485105 @default.
• W1999361421 cites W1966087026 @default.
• W1999361421 cites W1971505725 @default.
• W1999361421 cites W1978161524 @default.
• W1999361421 cites W1978277449 @default.
• W1999361421 cites W1985550740 @default.
• W1999361421 cites W1988128773 @default.
• W1999361421 cites W1988604278 @default.
• W1999361421 cites W2001067578 @default.
• W1999361421 cites W2025001924 @default.
• W1999361421 cites W2028974002 @default.
• W1999361421 cites W2053831986 @default.
• W1999361421 cites W2060486571 @default.
• W1999361421 cites W2064046486 @default.
• W1999361421 cites W2067026685 @default.
• W1999361421 cites W2067107057 @default.
• W1999361421 cites W2070350109 @default.
• W1999361421 cites W2075118249 @default.
• W1999361421 cites W2077992223 @default.
• W1999361421 cites W2089940123 @default.
• W1999361421 cites W2097546089 @default.
• W1999361421 cites W2099601272 @default.
• W1999361421 cites W2102979143 @default.
• W1999361421 cites W2108678557 @default.
• W1999361421 cites W2111995867 @default.
• W1999361421 cites W2113279029 @default.
• W1999361421 cites W2124805101 @default.
• W1999361421 cites W2127818427 @default.
• W1999361421 cites W2132458997 @default.
• W1999361421 cites W2132505348 @default.
• W1999361421 cites W2137712934 @default.
• W1999361421 cites W2139805666 @default.
• W1999361421 cites W2142393775 @default.
• W1999361421 cites W2146307231 @default.
• W1999361421 cites W2147918774 @default.
• W1999361421 cites W2149166027 @default.
• W1999361421 cites W2152798629 @default.
• W1999361421 cites W2153981371 @default.
• W1999361421 cites W2156789921 @default.
• W1999361421 cites W2158880436 @default.
• W1999361421 cites W2163991033 @default.
• W1999361421 cites W2164029652 @default.
• W1999361421 cites W2180920440 @default.
• W1999361421 cites W2396772514 @default.
• W1999361421 cites W2614763070 @default.
• W1999361421 cites W4245449645 @default.
• W1999361421 cites W4246296010 @default.
• W1999361421 doi "https://doi.org/10.1111/j.1365-2125.2008.03234.x" @default.
• W1999361421 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2526238" @default.
• W1999361421 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18782141" @default.
• W1999361421 hasPublicationYear "2008" @default.
• W1999361421 type Work @default.
• W1999361421 sameAs 1999361421 @default.
• W1999361421 citedByCount "58" @default.
• W1999361421 countsByYear W19993614212012 @default.
• W1999361421 countsByYear W19993614212013 @default.
• W1999361421 countsByYear W19993614212014 @default.
• W1999361421 countsByYear W19993614212015 @default.
• W1999361421 countsByYear W19993614212016 @default.
• W1999361421 countsByYear W19993614212017 @default.
• W1999361421 countsByYear W19993614212018 @default.
• W1999361421 countsByYear W19993614212019 @default.
• W1999361421 countsByYear W19993614212020 @default.
• W1999361421 countsByYear W19993614212021 @default.
• W1999361421 countsByYear W19993614212022 @default.
• W1999361421 countsByYear W19993614212023 @default.
• W1999361421 crossrefType "journal-article" @default.
• W1999361421 hasAuthorship W1999361421A5014426314 @default.
• W1999361421 hasAuthorship W1999361421A5017301961 @default.
• W1999361421 hasAuthorship W1999361421A5019974993 @default.
• W1999361421 hasAuthorship W1999361421A5034033183 @default.
• W1999361421 hasAuthorship W1999361421A5052505304 @default.
• W1999361421 hasBestOaLocation W19993614211 @default.
• W1999361421 hasConcept C126322002 @default.
• W1999361421 hasConcept C134018914 @default.
• W1999361421 hasConcept C164705383 @default.
• W1999361421 hasConcept C177713679 @default.
• W1999361421 hasConcept C198710026 @default.
• W1999361421 hasConcept C2778198053 @default.
• W1999361421 hasConcept C2779161974 @default.
• W1999361421 hasConcept C2910553456 @default.
• W1999361421 hasConcept C555293320 @default.
• W1999361421 hasConcept C71924100 @default.
• W1999361421 hasConcept C84393581 @default.
• W1999361421 hasConceptScore W1999361421C126322002 @default.
• W1999361421 hasConceptScore W1999361421C134018914 @default.

• next